Trending Now
Iterum Therapeutics plc (NASDAQ:ITRM) Submits New Drug Application For Oral Sulopenem...
Iterum Therapeutics plc (NASDAQ:ITRM) has announced the submission of a New Drug Application to the US FDA for sulopenem etzadroxil/probenecid. The application is for...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Markets in precarious situation heading into volatility
The markets are in a precarious situation right now. We are right off all-time highs and the corona virus is spreading.
MAKE IT MODERN
LATEST REVIEWS
MindMed (NASDAQ: MNMD) Reports Q3 2021 Financial Results and Commences Recruitment...
MindMed (NASDAQ: MNMD) has announced its financial results for the quarter ending September 30, 2021.
MindMed reported a net loss of $24.3 million in Q3...
MAKE IT MODERN
PERFORMANCE TRAINING
Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) Gives an Update on QRX003
Quoin Pharmaceuticals Inc (NASDAQ: QNRX) recently announced that it received the relevant authorisation from the Food and Drug Authority to proceed with the clinical...
RECIST Responses with First TC-210 Dose for Mesothelin-expressing Solid Tumors Had Positive Interim Data;...
We all know or have probably heard of someone who has cancer; another monster has taken the world by storm. The most unfortunate thing...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expects Approval For ORLADEYO In Japan And The US Soon:...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) transitions to a drug launching company to the patients with Hereditary Angioderma. The company expects approval for its ORLADEYO to...
Seattle Genetics Inc. (NASDAQ:SGEN) Enters Two Oncology Collaboration Agreements With Merck (NYSE:MRK)
Seattle Genetics Inc. (NASDAQ:SGEN) and Merck (NYSE:MRK) have entered two new strategic oncology partnerships for co-development and global commercialization of Ladiratuzumab Vedotin and co-development...
Trading SPY during the Santa Rally
The market continues to melt higher but with low volume this week. Not necessarily in a way that is has been helpful...
MAKE IT MODERN
